Role of lipid rafts in ceramide and nitric oxide signaling in the ischemic and preconditioned hearts

被引:31
|
作者
Der, P [1 ]
Cui, JH [1 ]
Das, DK [1 ]
机构
[1] Univ Connecticut, Sch Med, Cardiovasc Res Ctr, Farmington, CT 06030 USA
关键词
lipid rafts; caveolin; ceramide; sphingosine-l-phosphate; nitric oxides; eNOS; heart; ischemia/reperfusion;
D O I
10.1016/j.yjmcc.2005.10.005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Nitric oxide plays a crucial role in myocardial ischemia reperfusion injury as well as in myocardial adaptation to ischemic stress. To understand the dichotomy of nitric oxide behavior in the ischemic myocardium, isolated rat hearts were subjected to ischemia/reperfusion protocol. The tissue contents of sphingomyelin (SM), ceramide and sphingosine were determined by high performance thin layer chromatography (HPTLC). The myocardial plasma proteins were immunoprecipitated with caveolin-1 specific antibody. Ischemia/reperfusion resulted in the breakdown of SM with corresponding accumulation of ceramide and sphingosine. Immunoprecipitation with eNOS-specific antibody revealed the association of eNOS with caveolin-1 Fraction of the heart. Ischemia/reperfusion Caused a depression of contractile function and an increased apoptotic cell death and myocardial infarct size, which were reversed by preperfusing the hearts with desipramine, an sphingomyelinase inhibitor that also prevented ceramide accumulation and eNOS association with caveolin-1. The similar results were obtained when the hearts, were adapted to ischemic stress by subjecting them to repeated reversible ischemia and reperfusion. The results indicate that ischemia/reperfusion causes an increase in eNOS, which is unavailable to the ischemic heart because of its binding with caveolin-1. Ceramide plays a crucial role in this process, because prevention of ceramide formation either by myocardial adaptation to ischemia or with desipramine results in the inhibition of eNOS association with caveolin-1 thereby reducing myocardial ischemic reperfusion injury. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:313 / 320
页数:8
相关论文
共 50 条
  • [1] Role of lipid rafts in ceramide and nitric oxide signaling in the ischemic and preconditioned hearts
    Der, P
    Cui, JH
    Das, DK
    FASEB JOURNAL, 2006, 20 (05): : A1231 - A1231
  • [2] Role of lipid rafts in human placental nitric oxide production
    Leguizamon, Gustavo
    Aban, Cyntia
    Martinez, Nora
    Trigubo, Denise
    Herlax, Vanesa
    Mate, Sabrina
    Franchi, Ana
    Damiano, Alicia
    Farina, Mariana
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2017, 216 (01) : S331 - S331
  • [3] Nitric oxide inhibition of cyclic formation is dependent upon lipid rafts and caveolin signaling complexes
    Ostrom, RS
    Deckenback, J
    Hase, M
    Insel, PA
    CIRCULATION, 2003, 108 (17) : 206 - 206
  • [4] A role for lipid rafts in immune cell signaling
    Katagiri, YU
    Kiyokawa, N
    Fujimoto, J
    MICROBIOLOGY AND IMMUNOLOGY, 2001, 45 (01) : 1 - 8
  • [5] Role of lipid rafts in neurotrophic factor signaling
    Saarma, M
    Runeberg-Roos, P
    GLIA, 2003, : 16 - 16
  • [6] Ischemic preconditioning: Triggering role of nitric oxide-derived oxidants in isolated hearts
    Novalija, E
    Hogg, N
    Kevin, LG
    Camara, AKS
    Stowe, DF
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2003, 42 (05) : 593 - 600
  • [7] Lipid Rafts and Caveolae and Their Role in Compartmentation of Redox Signaling
    Patel, Hemal H.
    Insel, Paul A.
    ANTIOXIDANTS & REDOX SIGNALING, 2009, 11 (06) : 1357 - 1372
  • [8] Role of tissue factor disulfides and lipid rafts in signaling
    Pendurthi, Usha R.
    Rao, L. Vijaya Mohan
    THROMBOSIS RESEARCH, 2008, 122 : S14 - S18
  • [9] The role of lipid rafts on signaling by heterotrimeric g proteins
    Miura, Y
    Jones, TLZ
    MOLECULAR BIOLOGY OF THE CELL, 1999, 10 : 306A - 306A
  • [10] The role of protein kinase C in ischemic/reperfused preconditioned isolated rat hearts
    Tosaki, A
    Maulik, N
    Engelman, DT
    Engelman, RM
    Das, DK
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1996, 28 (05) : 723 - 731